Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)

29
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
09/15/2014 09/16/2014 09/17/2014 09/18/2014 09/19/2014 Date
75.6(c) 73.6(c) 74.51(c) 74.69(c) 75.88(c) Last
72 031 55 201 50 997 48 414 321 679 Volume
-0.55% -2.65% +1.24% +0.24% +1.59% Change
More quotes
Company
MorphoSys AG is engaged in the development of antibodies for therapeutic, diagnostic, and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development, and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
Sector
Biotechnology & Medical Research
Calendar
09/18 | 08:45amPresentation
Surperformance© rating of MorphoSys AG
Trading Rating : Investor Rating :
More about the company
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 62,6 M
EBIT 2014 -14,2 M
Net income 2014 -13,4 M
Finance 2014 275 M
Yield 2014 -
Sales 2015 71,1 M
EBIT 2015 -0,23 M
Net income 2015 -8,23 M
Finance 2015 261 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 27,6x
EV / Sales 2015 24,5x
Capitalization 2 001 M
More Financials
Latest news on MORPHOSYS AG
5d ago MORPHOSYS : Receives Research Grant to Develop Novel Therapeutic Antibodies Targ..
5d ago MORPHOSYS : Receives Research Grant to Develop Novel Therapeutic Antibodies Targ..
09/04 MORPHOSYS : to Present at Six Investor Conferences in September
08/27 EMERGENT BIOSOLUTIONS : and MorphoSys Sign License Agreement to Co-Develop and C..
08/20 MORPHOSYS : and Emergent BioSolutions Sign License Agreement to Co-Develop and C..
08/20 MORPHOSYS : to Host Conference Call on License Agreement with Emergent to Co-Dev..
08/19 EMERGENT BIOSOLUTIONS : MorphoSys and Emergent BioSolutions Sign License Agreeme..
08/06 MORPHOSYS : Patent Application Titled "Use of c-Fms Antagonists" Published Onlin..
07/28 CELGENE : MorphoSys Provides Update on the Company's Proprietary Drug Portfolio
07/28 MorphoSys AG Reports Results for the First Six Months of 2014
07/23 GALAPAGOS : MorphoSys and Galapagos Advance Joint Antibody Program in Inflammato..
07/21 MORPHOSYS : to Host Q2 2014 Conference Call on 28 July 2014
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
MorphoSys AG : Income Statement Evolution
More Financials
EPS Revisions
MorphoSys AG : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF